Targets › MUC16
5 programs from 5 companies in 10 trials: 7 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. (UniProt, Q8WXI7)
Open in Phaseline: the race on MUC16, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CanariaBio | Oregovomab Mucin-16 other | MUC16 | Phase 3 | Carcinoma, Ovarian Epithelial; Recurrent Ovarian Cancer; Ovarian Neoplasm Epithelial; Ovarian Cancer by FIGO Stage | Dec 2026 |
| Beijing Biotech | EB-NK-MF CAR-NK cells Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit | MSLN, FOLR1, MUC16, TROP2 | Phase 1 | Advanced Solid Tumors; Epithelial Ovarian Cancer | Feb 2027 |
| Memorial Sloan Kettering Cancer Center | 4H11-28z/fIL-12/EGFRt+ genetically-modified T cells CAR-T cells engineered to target MUC16ecto antigen and secrete IL-12 | MUC16 | Phase 1 | Solid Tumors | Aug 2027 |
| Whitehawk Therapeutics | HWK-016 MUCIN-16-targeted antibody-drug conjugate | MUC16 | Phase 1 | PROC | Feb 2028 |
| Regeneron Pharmaceuticals | 27T51 MUC16-targeting CAR T cell therapy | MUC16 | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
Epithelial Ovarian Cancer (3) Carcinoma, Ovarian Epithelial (1) Recurrent Ovarian Cancer (1) Ovarian Neoplasm Epithelial (1) Ovarian Cancer by FIGO Stage (1) Advanced Solid Tumors (1) Solid Tumors (1) PROC (1)
mixed (4), antibody (1)
CanariaBio (1) Beijing Biotech (1) Memorial Sloan Kettering Cancer Center (1) Regeneron Pharmaceuticals (1) Whitehawk Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.